Resources

A human iPSC-based platform to screen therapeutics for ALS usingspecific and robust phenotypic assays poster

Written by Ncardia Stem Cell Experts | April 30, 2026

This poster presents Ncardia’s human iPSC-derived motor neuron platform, designed to model key ALS disease phenotypes and enable high-throughput screening of therapeutic candidates in a physiologically relevant system. 

Download it now for a closer look at:

  • How CRISPR-engineered TDP-43 mutant motor neurons replicate core ALS hallmarks, including protein mislocalization, aggregation, and downstream molecular effects 
  • Quantitative assays measuring TDP-43 pathology, STMN2 reduction and mis-splicing, neurofilament-L secretion, and electrophysiological dysfunction 
  • How complex co-culture systems with astrocytes enhance physiological relevance and capture disease-specific cellular interactions 
  • Evidence that the platform can be miniaturized to 384-well format, supporting scalable, high-throughput compound screening 
  • Proof-of-concept data showing successful gene therapy intervention, including reduced TDP-43 aggregation following treatment 
Download the Poster